SOM0226

Small molecule

SSOM Innovation Biotech SA

SOM0226 is one of 20 small molecule programs targeting Polyneuropathy. It is currently in development.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

PolyneuropathyActive, not recruiting

PolyneuropathyPhase 1/Phase 2

Active, not recruiting

Competition

Competitive Landscape

25 competitors in Polyneuropathy

#DrugCompanyPhaseTrials

Keppra

UCB

Approved

2 2

Tofranil

Sanofi

Approved

1 3

Lexapro

AbbVie

Approved

1 4

Vyndaqel

KK-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc.

Approved

4 5

Lyrica

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

1 6

Dilantin

VViatris Specialty LLC

Rituxan

Wainua (autoinjector)

AstraZeneca

Phase 3

2 9

Fx-1006a

Pfizer

Phase 3

1 10

Lipoic Acid

NNovaMed Pharmaceuticals Inc.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Polyneuropathy1 trial

Study of SOM0226 in Familial Amyloid Polyneuropathy

Completed·SSOM Innovation Biotech SA·Phase 1/2·NCT02191826·17 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for SOM0226. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — SOM0226 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for SOM0226. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — SOM Innovation Biotech SA company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Company: SSOM Innovation Biotech SA

SOM0226

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Polyneuropathy1 trial

References

Drug Info

Quick Facts

Related News